These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 37059508)

  • 1. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Howard JF; Bresch S; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Lowcock R; Vanderkelen M; Leite MI;
    Lancet Neurol; 2023 May; 22(5):395-406. PubMed ID: 37059508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
    Bril V; Drużdż A; Grosskreutz J; Habib AA; Mantegazza R; Sacconi S; Utsugisawa K; Vissing J; Vu T; Boehnlein M; Bozorg A; Gayfieva M; Greve B; Woltering F; Kaminski HJ;
    Lancet Neurol; 2023 May; 22(5):383-394. PubMed ID: 37059507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
    Howard JF; Bresch S; Farmakidis C; Freimer M; Genge A; Hewamadduma C; Hinton J; Hussain Y; Juntas-Morales R; Kaminski HJ; Maniaol A; Mantegazza R; Masuda M; Nowak RJ; Sivakumar K; Śmiłowski M; Utsugisawa K; Vu T; Weiss MD; Zajda M; Bloemers J; Boroojerdi B; Brock M; de la Borderie G; Duda PW; Vanderkelen M; Leite MI;
    Ther Adv Neurol Disord; 2024; 17():17562864241243186. PubMed ID: 38638673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
    Habib AA; Sacconi S; Antonini G; Cortés-Vicente E; Grosskreutz J; Mahuwala ZK; Mantegazza R; Pascuzzi RM; Utsugisawa K; Vissing J; Vu T; Wiendl H; Boehnlein M; Greve B; Woltering F; Bril V
    Ther Adv Neurol Disord; 2024; 17():17562864241273036. PubMed ID: 39297052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
    Weiss MD; Freimer M; Leite MI; Maniaol A; Utsugisawa K; Bloemers J; Boroojerdi B; Howard E; Savic N; Howard JF
    J Neurol; 2024 May; 271(5):2758-2767. PubMed ID: 38400914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis.
    de la Borderie G; Chimits D; Boroojerdi B; Brock M; Duda PW; Grimson F; Mahoney P; Strimenopoulou F; Cutter G; Aban I; Brauner S; Petersson M; Howard JF; Bennett N
    Ther Adv Neurol Disord; 2024; 17():17562864241279125. PubMed ID: 39314260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
    Granit V; Benatar M; Kurtoglu M; Miljković MD; Chahin N; Sahagian G; Feinberg MH; Slansky A; Vu T; Jewell CM; Singer MS; Kalayoglu MV; Howard JF; Mozaffar T;
    Lancet Neurol; 2023 Jul; 22(7):578-590. PubMed ID: 37353278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ravulizumab: A Review in Generalised Myasthenia Gravis.
    Kang C
    Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
    Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
    Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
    Mammen AL; Amato AA; Dimachkie MM; Chinoy H; Hussain Y; Lilleker JB; Pinal-Fernandez I; Allenbach Y; Boroojerdi B; Vanderkelen M; Delicha EM; Koendgen H; Farzaneh-Far R; Duda PW; Sayegh C; Benveniste O
    Lancet Rheumatol; 2023 Feb; 5(2):e67-e76. PubMed ID: 36923454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.
    Allen JA; Lin J; Basta I; Dysgaard T; Eggers C; Guptill JT; Gwathmey KG; Hewamadduma C; Hofman E; Hussain YM; Kuwabara S; Le Masson G; Leypoldt F; Chang T; Lipowska M; Lowe M; Lauria G; Querol L; Simu MA; Suresh N; Tse A; Ulrichts P; Van Hoorick B; Yamasaki R; Lewis RA; van Doorn PA;
    Lancet Neurol; 2024 Oct; 23(10):1013-1024. PubMed ID: 39304241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
    Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
    Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.